Evotec Secures Grants for Tuberculosis Treatment Enhancement

Evotec SE has received two grants from the Gates Foundation to advance tuberculosis (TB) treatment. These grants, continuing from four previous ones, total $9.9 million. The funding aims to foster the discovery and development of novel drug candidates and to evaluate advanced drug regimens for clinical testing.

The objective is to broaden the pipeline of TB drug candidates, prioritizing those promising combinations for clinical trials. Current TB treatments are lengthy and complex, impacting patient compliance, particularly in drug-resistant cases. These grants will utilize Evotec's AI-enabled platforms for drug discovery and evaluation.

Notably, one grant is allocated for discovering small molecules targeting all TB forms. The other focuses on nonclinical characterization of next-generation drug combinations, including Long Acting Injectables, a potential innovation in TB therapy.